Abstract:Abstract Background Many patients experience primary treatment resistance when treated with ustekinumab for ulcerative colitis (UC). Predictive clinical parameters would allow such individuals to be identified pre-treatment so alternative strategies could be initiated. We explored the utility of the different histological features present in baseline samples to predict ustekinumab resistance. Methods We assessed the total Geboes score (TG) (0–22, least to most severe), and the epithelial and lamina propria neutrophil subscores (EpiN and LpN, respectively) (both 0–3) in a subset of patients with moderate-to-severely active UC (n = 448) enrolled in the phase 3 UNIFI study that evaluated the efficacy of ustekinumab therapy. We explored the relationships between histological parameters and clinical indices of activity, including faecal calprotectin (FCP), CRP, Mayo score, and treatment outcomes (clinical remission, endoscopic healing and mucosal healing at week 8, and disease clearance, which combines these all) using Spearman rank correlation. Area under the receiver operating characteristic curve (AUC) analyses were performed (presented with 95% confidence interval, CI). Analyses were performed using R 4.2.3 (Vienna, Austria) and GraphPad Prism (v 9.5.1). Results TG correlated highly with EpiN (ρ = 0.804, p < 0.0001) but did not correlate with LpN (ρ = 0.082, p = 0.07). Neither EpiN (ρ = 0.081, p = 0.09) nor LpN (ρ = -0.011, P = 0.82) correlated with FCP, though EpiN correlated weakly with log10FCP (ρ = 0.113, p = 0.017). Full Mayo score correlated with EpiN (ρ = 0.23, p < 0.0001) and TG (ρ = 0.23, < 0.0001). Of the patients with pre-treatment EpiN of 0, 23.1%, 26.9%, 23.1% and 19.2% experienced clinical remission, endoscopic healing, mucosal healing and disease clearance, respectively. Response rates incrementally reduced as EpiN increased, such that 4.2%, 12.5%, 8.3% and 4.2% of patients with EpiN of 3 achieved these outcomes, respectively. Similar trends were seen with tertiles of TG, though not with LpN. EpiN and TG predict mucosal healing with AUC 0.59 (CI: 0.50 - 0.68; p = 0.044) and 0.61 (CI: 0.52 - 0.70; p = 0.016), respectively. The addition of other clinical variables did not improve performance of the models. Conclusion There is weak or insignificant correlation between Geboes score parameters and other clinical indices of UC activity. EpiN and TG, but not LpN, stratify patients’ response to ustekinumab, with almost 6-fold difference in clinical remission between high and low EpiN. TG and EpiN predict resistance to ustekinumab, suggesting that the epithelial inflammatory milieu may be key to driving resistance to ustekinumab and possibly other therapies. This supports recent evidence highlighting the role of neutrophils in resistant UC.

P279 Excessive accumulation of neutrophils in the epithelium, but not lamina propria, predicts resistance to ustekinumab in ulcerative colitis

P348 Increased pre-treatment faecal calprotectin concentration predicts resistance to ustekinumab induction in ulcerative colitis

DOP62 A core molecular resistome characterised by extracellular matrix dysregulation and neutrophil degranulation predicts resistance to multiple therapies in Ulcerative Colitis

P385 Epithelial neutrophil localization and Claudin-2 immunohistochemical "leaky gut" expression are innovative predictors of outcomes in Ulcerative Colitis patients in endoscopic remission

DOP31 Gene correlation network analyses reveal transcript modules and pathogenic mechanisms associated with resistance and response to ustekinumab therapy in Ulcerative Colitis

P475 Potential of molecular remission: tissue neutrophil elastase is better than histological activity for predicting long-term relapse in patients with Ulcerative Colitis in endoscopic remission

P576 Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy

Identifying hub genes in response to ustekinumab and the impact of ustekinumab treatment on fibrosis in Crohn's disease

P021 Higher TNFα and IL-6 mucosal levels in ulcerative colitis patients with more severe endoscopic activity

Molecular characterization of response to etrolizumab and anti-TNF reveals treatment resistance in ulcerative colitis is associated with the abundance of residual neutrophil subsets and inflammatory fibroblast populations

P336 Exploring Extracellular Matrix Markers in Ulcerative Colitis: Degradation and Formation Insights

DOP71 TREM1, OSM and a co-expressed transcriptional module are core components of the molecular resistome to anti-cytokine therapy in Ulcerative Colitis

P699 Identification of A Novel Activated NK-Associated Gene Score Associated with Diagnosis and Biological Therapy Response in Ulcerative Colitis

P886 Ustekinumab concentrations in induction are associated with mid-term endoscopic outcomes in patients with inflammatory bowel disease

P592 Higher predictive power of epigenetic signatures for response to vedolizumab and ustekinumab in anti-TNF naïve patients with active Crohn’s disease

The Potential of Molecular Remission: Tissue Neutrophil Elastase Is Better Than Histological Activity for Predicting Long-Term Relapse in Patients With Ulcerative Colitis in Endoscopic Remission

P167 Remodelling of the colonic molecular landscape in patients failing anti-TNF therapy highlights dysregulation of the extracellular matrix in ulcerative colitis

Insights into Therapeutic Response Prediction for Ustekinumab in Ulcerative Colitis Using an Ensemble Bioinformatics Approach

P1195 Identification of immune cell infiltration and potential candidate biomarker in anti-IL 12/23 treated Crohn’s disease patients by integrated bioinformatics analysis and machine learning

OP21 Spatial Transcriptomics of Pre-treatment Biopsies Revealing Molecular Maturation State and Chronic Crypt Damage, Reflecting Histological Severity, as Predictors of Primary Responsiveness to TNF-α Inhibitors in Bio-naive Ulcerative Colitis Patients

Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis